Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications
BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
[HTML][HTML] Everolimus Combined With Gefitinib in Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I/II Results and Signaling Pathway Implications
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - ncbi.nlm.nih.gov
Background The effects of mammalian target of rapamycin (mTOR) inhibition are limited by
feedback reactivation of receptor tyrosine kinase signaling in PTEN-null tumors, thus we …
feedback reactivation of receptor tyrosine kinase signaling in PTEN-null tumors, thus we …
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - portal.research.lu.se
The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback
reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null …
reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null …
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - lup.lub.lu.se
The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback
reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null …
reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null …
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - pubmed.ncbi.nlm.nih.gov
Background The effects of mammalian target of rapamycin (mTOR) inhibition are limited by
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - infona.pl
BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - europepmc.org
Background The effects of mammalian target of rapamycin (mTOR) inhibition are limited by
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
DE Rathkopf, SM Larson, A Anand, MJ Morris… - Cancer, 2015 - europepmc.org
Background The effects of mammalian target of rapamycin (mTOR) inhibition are limited by
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …